Pilot trial of etanercept in the treatment of inclusion-body myositis
- 24 January 2006
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 66 (1_suppl_1), S123-S124
- https://doi.org/10.1212/01.wnl.0000192258.32408.54
Abstract
Inclusion-body myositis (IBM) is an inflammatory muscle disease that has proven resistant to treatment. Tumor necrosis factor molecules have been detected in muscle biopsies from patients with IBM. Etanercept is a TNFα receptor fusion protein that binds and inactivates tumor necrosis factor. Nine patients were treated with etanercept at a dose of 25 mg, two times a week for an average of 17 ± 6.1 months. Each patient was evaluated using quantitative strength testing. Their data were compared to two different control groups. The first control group consisted of patients who participated in trials of beta-interferon-1A and had received placebo. There was no significant difference. The second control group was a natural history cohort of IBM patients. There was no statistically significant difference between the treated group and the natural history group at 6 and 12 months when looking at elbow flexors, or 6 months when looking at hand grip. In the treated patients there was a small but significant improvement (p = 0.002) in handgrip at 12 months.This publication has 16 references indexed in Scilit:
- Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositisNeurology, 2001
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisThe New England Journal of Medicine, 2000
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateThe New England Journal of Medicine, 1999
- Local expression of cytokines in idiopathic inflammatory myopathiesNeuropathology and Applied Neurobiology, 1998
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinThe New England Journal of Medicine, 1997
- A Prospective, Quantitative Study of the Natural History of Facioscapulohumeral Muscular Dystrophy (FSHD)Neurology, 1997
- Inclusion body myositis and myopathiesAnnals of Neurology, 1995
- Inclusion body myositisNeurology, 1995
- The Treatment of Inclusion Body MyositisMedicine, 1993
- Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cellsAnnals of Neurology, 1984